Hydroxyprogesterone Caproate

Hydroxyprogesterone Caproate

SCHEMBL5330

CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PGR

The experimentally established mechanism targets of Hydroxyprogesterone Caproate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR known ✓ P06401 4/20 1.00
LMNA P02545 6/20 1.00
NR3C1 P04150 5/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
HIF1A Q16665 4/20 1.00
CYP3A4 P08684 4/20 1.00
KMT2A Q03164 3/20 1.00
MAPT P10636 3/20 1.00
MEN1 O00255 2/20 1.00
ADORA3 P0DMS8 2/20 1.00
SLC6A3 Q01959 2/20 1.00
NPSR1 Q6W5P4 2/20 1.00
HPGD P15428 1/20 1.00
MLNR O43193 1/20 1.00
NR1I2 O75469 1/20 1.00
HTT P42858 1/20 1.00
PDE4D Q08499 1/20 1.00
PDE3A Q14432 1/20 1.00
AR P10275 2/20 0.67
NR3C2 P08235 4/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroxyprogesterone Caproate SCHEMBL21497316 1.00 LMNA (1.00) LMNANR3C1SMN1; SMN2HIF1APGR
Hydroxyprogesterone Caproate SCHEMBL14649335 1.00 LMNA (1.00) LMNANR3C1SMN1; SMN2HIF1APGR
Hydroxyprogesterone Caproate SCHEMBL94788 1.00 LMNA (1.00) LMNANR3C1SMN1; SMN2HIF1APGR
Hydroxyprogesterone Caproate SCHEMBL508890 1.00 LMNA (1.00) LMNANR3C1SMN1; SMN2HIF1APGR
Hydroxyprogesterone Caproate SCHEMBL16812894 1.00 LMNA (1.00) LMNANR3C1SMN1; SMN2HIF1APGR
Hydroxyprogesterone Caproate SCHEMBL17517045 1.00 LMNA (1.00) LMNANR3C1SMN1; SMN2HIF1APGR
SCHEMBL5425550 0.99 LMNA (0.98) LMNANR3C1SMN1; SMN2HIF1APGR
SCHEMBL353516 0.99 LMNA (0.98) LMNANR3C1SMN1; SMN2HIF1APGR
SCHEMBL14656870 0.99 LMNA (0.98) LMNANR3C1SMN1; SMN2HIF1APGR
SCHEMBL17519899 0.98 LMNA (0.96) LMNANR3C1SMN1; SMN2HIF1APGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 17682 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-03-17 US claimed
EP-4525938-B1 RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS BAYER AG (DE) 2026-03-11 EP claimed
EP-4704832-A2 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS Biohaven Therapeutics Ltd. (VG) 2026-03-11 EP claimed
EP-4689823-A1 METHOD AND SYSTEM FOR DETERMINING A FAULTY COMPONENT OF AN AIRCRAFT SAFRAN AIRCRAFT ENGINES (FR) 2026-02-11 EP claimed
US-20260027215-A1 COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV RECEPTIVE BIO INC (US) 2026-01-29 US claimed
US-20260022117-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS ARVINAS OPERATIONS INC (US) 2026-01-22 US claimed
US-20260000613-A1 INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS FORDOZ PHARMA CORP. (US) 2026-01-01 US claimed
US-12485178-B2 Bifunctional small molecules to target the selective degradation of circulating proteins YALE UNIVERSITY (US) 2025-12-02 US claimed
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS INC (US) 2025-11-27 US claimed
US-20250332274-A1 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS UNIV YALE (US) 2025-10-30 US claimed
WO-1993019668-A1 METHOD AND KIT FOR IMAGING AND TREATING ORGANS AND TISSUES IMMUNOMEDICS, INC. (US) 1993-10-14 WO claimed
US-5211952-A Drug delivery of gonadotropin hormone releasing hormones for time release UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1993-05-18 US claimed
WO-1993007749-A1 PEST CONTROL COMPOSITIONS AKZO NOBEL N.V. (NL) 1993-04-29 WO claimed
EP-0538443-A1 METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. UNIV SOUTHERN CALIFORNIA (US) 1993-04-28 EP claimed
WO-1993000058-A1 SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION NOVEN PHARMACEUTICALS, INC. (US) 1993-01-07 WO claimed
WO-1992018107-A1 METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1992-10-29 WO claimed
WO-1989005663-A1 TRANSDERMAL ESTROGEN/PROGESTIN DOSAGE UNIT, SYSTEM AND PROCESS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1989-06-29 WO claimed
WO-1986003590-A1 DEVICE AND METHOD FOR ANALYSIS OF BIOLOGICAL MATERIAL BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1986-06-19 WO claimed
EP-0010964-A1 Ravidomycin, process of preparation and pharmaceutical compositions containing same AYERST, MCKENNA AND HARRISON INC. (CA) 1980-05-14 EP claimed
US-4014988-A Method for treating hypermenorrhea with uterine therapeutic system ALZA CORPORATION (US) 1977-03-29 US claimed